Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. With pioneering medical research achievements, education programs defining the future of healthcare, and wide-ranging community benefit activities, Cedars-Sinai is setting new standards for quality and innovation in patient care.
Beginning in 1902 as a 12-bed hospital in the Angelino Heights neighborhood of Los Angeles, today Cedars-Sinai serves more than 1 million people each year in over 40 locations, with more than 4,500 physicians and nurses and 1,500 research projects in motion.
Cedars-Sinai fulfills its vital mission to the community by investing in programs and services to improve the health status of the community. Cedars-Sinai works closely with schools, FQHC, local government, senior centers and other agencies to improve community health, better meet community needs, and to expand the capacity of other organizations to serve those who are most vulnerable, maximizing the impact of joint efforts to improve lives.
Cedars-Sinai is a nonprofit, independent healthcare organization committed to improving the health status of the communities they serve through:
Quality patient care is Cedars-Sinai’s priority. Providing excellent clinical and service quality, offering compassionate care, and supporting research and medical education are essential to its mission. This mission is founded in the ethical and cultural precepts of the Judaic tradition, which inspire devotion to the art and science of healing and to the care Cedars-Sinai gives their patients and staff.
Cedars-Sinai will continue as the leading healthcare organization in Los Angeles, while enhancing its position as a recognized leader among the nation’s most respected, admired, and trusted healthcare organizations. In fulfilling this role, Cedars-Sinai will:
To achieve this, Cedars-Sinai will:
The Samuel Oschin Comprehensive Cancer Institute’s mission is to advance breakthrough research and exquisite care as well as provide exceptional support to faculty and staff. Researchers and clinicians continue to pioneer and advance novel clinical studies while strengthening their commitment to improve patient outcomes and access to top-quality cancer care. Top cancer researchers serve as national leaders in the field and published more than 350 articles in the last year in prestigious peer-reviewed journals including Cancer, Journal of the American Medical Association, Lancet Oncology, Nature, and the New England Journal of Medicine. By exploring topics from cancer clinical trials to pathological characteristics of the disease and cancer diagnostics, the authors of these articles broadened the world’s knowledge around the underpinnings of the disease, its prevention and diagnosis, and the care of patients in need of more powerful and effective treatments.
Notably, in July 2018, renowned cancer clinician and scientist Dan Theodorescu, MD, PhD, was named the PHASE ONE Foundation Distinguished Chair and Director at the Samuel Oschin Comprehensive Cancer Institute. Dr. Theodorescu, a nationally recognized translational cancer researcher and leading expert in bladder cancer, is directing the oncology enterprise at Cedars-Sinai. Previously, from 2010 until 2018, he was director of the University of Colorado Cancer Center and a distinguished university professor. He brings a compelling vision for leading what he sees as three revolutions shaping modern cancer care: using precision medicine strategies to personalize treatments, tapping “big data” to solve difficult research and treatment questions, and employing population health ideas to reduce health inequities and improve access to care for entire populations.
Dr. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as the discovery of new drugs for cancer. Examples include the discovery of genes that regulate tumor growth and metastasis (RhoGDI2, AGL, GON4L), and novel biomarkers (DNA/NGS, RNA and proteomic) and concepts for precision therapeutic approaches such as the COXEN principle, which is being tested in national (SWOG) clinical trials. He also conceptualized the approach and then led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in cancer. This drug was awarded a U.S. patent and is in commercial development. His laboratory is funded by grants from the NIH-NCI.
The Samuel Oschin Comprehensive Cancer Institute is in an exciting time of progress and advancement with a passion and goal to enhance quality of life for patients and their families across the Cedars-Sinai community.
The Executive Director of Development, Cancer is responsible for identification, qualification, cultivation, and solicitation of prospective major and principal gift donors for all programs and services, leading to major funding of Cedars-Sinai’s highest priorities in Cancer. The Executive Director will lead a team of four professional senior fundraisers and support staff, while managing all aspects of his/her team’s personnel initiatives and managing relevant budgets in assigned areas. The Executive Director will collaborate with assigned physicians and Cedars-Sinai’s leadership; work with various committee volunteers and Board leadership to plan and implement programs and events; and develop relationships with new constituents.
All qualified candidates will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, veteran status, or any other characteristic protected by law.
Please email your cover letter and resume in confidence to:
Senior Vice President, and Director, New York, Principal
Development Guild DDI